BinD 19

Drug Profile

BinD 19

Alternative Names: BinD19

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shenzhen BinDeBio
  • Developer Shenzhen BinDeBio; The First Affiliated Hospital of Zhengzhou University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma

Most Recent Events

  • 02 Mar 2017 Phase-I/II clinical trials in Acute lymphoblastic leukaemia and Lymphoma (In children, In adolescents, In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT03156101)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top